Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Treatment of severe hypoglycemia outside of the hospital setting is limited to glucagon formulations requiring reconstitution before use, which may lead to erroneous or delayed glucagon administration. We compared the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics and safety and tolerability of different doses of dasiglucagon, a novel soluble glucagon analog, with approved pediatric and full doses of GlucaGen in insulin-induced hypoglycemia in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion. RESULTS: Dasiglucagon demonstrated a dose-dependent and rapid increase in plasma concentrations, reaching a maximum at ∼35 min with a half-life of ∼0.5 h. Dasiglucagon rapidly increased plasma glucose (PG) by ≥20 mg/dL (9–14 min) to PG ≥70 mg/dL (within 6–10 min), similar to GlucaGen, but with a longer-lasting and greater effect on PG. All patients on both treatments reached these end points within 30 min (predefined success criteria). Both treatments were well tolerated. Nausea was the most frequent adverse event, occurring at a similar rate (44–56%). CONCLUSIONS: Dasiglucagon was well tolerated and showed an early PD response similar to that of GlucaGen at corresponding doses, suggesting comparable clinical effects of the two glucagon formulations. Dasiglucagon has the potential to become an effective and reliable rescue treatment for severe hypoglycemia in a ready-to-use pen.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These new FDAeapproved formulations have demonstrated glycemic responses similar to standard glucagon formulations for the treatment of hypoglycemia but without the need of reconstitution.1230”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1230]
Citations
Cites
(2) Classification and diagnosis of diabetes
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s005 · Cited by 1,841
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602
Wood, J. R., Miller, K. M., Maahs, D. M., Beck, R. W., DiMeglio, L. A., Libman, I. M., Quinn, M., Tamborlane, W. V., Woerner, S. E., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1959 · Cited by 415
El-Khatib, F. H., Balliro, C., Hillard, M. A., Magyar, K. L., Ekhlaspour, L., Sinha, M., Mondesir, D., Esmaeili, A., Hartigan, C., Thompson, M. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32567-3 · Cited by 254
Choudhary, P., Rickels, M. R., Senior, P. A., Vantyghem, M.-C., Maffi, P., Kay, T. W., Keymeulen, B., Inagaki, N., Saudek, F., Lehmann, R., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0090 · Cited by 233 · cited 1×
“As advantageous as this design was for creating similar baseline conditions, this setup is different from the usual clinical causes of severe hypoglycemia, whichmost often comprise of insulin dosing errors, exercise, and alcohol consumption (30).”
BackgroundHaidar, A., Legault, L., Messier, V., Mitre, T. M., Leroux, C., & Rabasa-Lhoret, R. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70226-8 · Cited by 214 · cited 1×
“tems have been demonstrated in adults, adolescents, and children (20,21).”
BackgroundTreatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
Kedia (2011) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s20633 · Cited by 131
Haidar, A., Legault, L., Matteau‐Pelletier, L., Messier, V., Dallaire, M., Ladouceur, M., & RABASA-LHORET, R. P. R. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00141-2 · Cited by 129 · cited 1×
“tems have been demonstrated in adults, adolescents, and children (20,21).”
BackgroundRickels, M. R., Ruedy, K. J., Foster, N. C., Piché, C. A., Dulude, H., Sherr, J. L., Tamborlane, W. V., Bethin, K. E., DiMeglio, L. A., Wadwa, R. P., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1498 · Cited by 128
Mini-Dose Glucagon Rescue for Hypoglycemia in Children With Type 1 Diabetes
Haymond, M. W., & Schreiner, B. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.643 · Cited by 114 · cited 2×
“cemia rescue therapy, glucagondoses in the artificial pancreas setting are much smaller and have been reported to be effective in themanagement of mild or expected forthcoming hypoglycemia in a range of 20–150 mg in children and adolescents with type 1 diabetes (22,23).”
Background
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Quattrin, T., Mastrandrea, L. D., & Walker, L. S. K. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00223-4 · Cited by 244
“Unfortunately, however, these preventative strategies are difficult to implement, especially if heathier habits are not pursued by the extended household or family.”
BackgroundStructural insights into differences in G protein activation by family A and family B GPCRs
Hilger, D., Kumar, K. K., Hu, H., Pedersen, M. F., O’Brien, E. S., Giehm, L., Jennings, C., Eskici, G., Inoue, A., Lerch, M., et al. (2020) · Science · doi:10.1126/science.aba3373 · Cited by 152
“Ligands and their sources were as follows: (-)-isoproterenol hydrochloride (Sigma-Aldrich) for b2AR; serotonin (5-hydroxytryptamine hydrochloride; FUJIFILMWakoPureChemical) for 5-HT4; prostaglandin D2 (Cayman Chemical) for DP; histamine dihydrochloride (FUJIFILM Wako Pure Chemical) for H2R; arginine vasopressin (Pepti…”
MethodInfluentialCastle, J. R., El Youssef, J., Wilson, L. M., Reddy, R., Resalat, N., Branigan, D., Ramsey, K., Leitschuh, J., Rajhbeharrysingh, U., Senf, B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0228 · Cited by 152
“A stable glucagon formulation to enable longer-term use is not yet commerciallyavailable,althoughmultiple formulations are in development (33,34).”
BackgroundCabri, W., Cantelmi, P., Corbisiero, D., Fantoni, T., Ferrazzano, L., Martelli, G., Mattellone, A., & Tolomelli, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.697586 · Cited by 119
“, 2020) for its very low stability in physiological formulations and its consequent high tendency to aggregate in few hours, after reconstitution (Hӧvelmann et al., 2018).”
BackgroundPihoker, C., Forsander, G., Fantahun, B., Virmani, A., Corathers, S. D., Benitez‐Aguirre, P., Fu, J., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12757 · Cited by 117
“Parents should make sure glucagon is available at home and during travel for emergencies.(115, 116)”
Domingo‐Lopez, D. A., Lattanzi, G., Schreiber, L. H. J., Wallace, E. J., Wylie, R., O’Sullivan, J., Dolan, E. B., & Duffy, G. P. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114280 · Cited by 125
Güemes, M., Rahman, S. A., Kapoor, R. R., Flanagan, S. E., Houghton, J., Misra, S., Oliver, N. S., Dattani, M., & Shah, P. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09548-7 · Cited by 101
Castellanos, L. E., Balliro, C. A., Sherwood, J. S., Jafri, R., Hillard, M. A., Greaux, E., Selagamsetty, R., Zheng, H., El-Khatib, F. H., Damiano, E. R., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1086 · Cited by 74
“NCT03840278, ClinicalTrials.gov) was the first human study to test the bihormonal iLet configuration and the first multiday use of dasiglucagon in people with T1D (2).”
BackgroundInfluentialMartin, V., Jadhav, S. V., Egelund, P. H. G., Liffert, R., Johansson, H., Krüger, T., Haselmann, K. F., Quement, S. T. L., Alberício, F., Dettner, F., et al. (2021) · Green Chemistry · doi:10.1039/d1gc00603g · Cited by 83
Glucose-Fueled Peptide Assembly: Glucagon Delivery via Enzymatic Actuation
Yu, S., Xian, S., Ye, Z., Pramudya, I., & Webber, M. J. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c04570 · Cited by 81
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O’Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 71
“Furthermore, it has been suggested that postprandial hyperglucagonaemia and impaired glucagon response to hypoglycaemia are features of T1DM (52).”
BackgroundInfluentialStable Liquid Glucagon: Beyond Emergency Hypoglycemia Rescue
Wilson, L. M., & Castle, J. R. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818757795 · Cited by 63
“0 mg dose.(57) To date, data suggest similar side effect profile to conventional glucagon with mild injection site reactions and dose dependent nausea and vomiting.”
BackgroundInfante, M., Baidal, D. A., Rickels, M. R., Fabbri, A., Skyler, J. S., Alejandro, R., & Ricordi, C. (2021) · Artificial Organs · doi:10.1111/aor.14023 · Cited by 66
Algorithms for Automated Insulin Delivery: An Overview
Thomas, A., & Heinemann, L. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211008442 · Cited by 67
Negative allosteric modulation of the glucagon receptor by RAMP2
Kumar, K. K., O’Brien, E. S., Habrian, C. H., Latorraca, N. R., Wang, H., Tuneew, I., Montabana, E. A., Marqusee, S., Hilger, D., Isacoff, E. Y., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.028 · Cited by 60
Pieber, T. R., Aronson, R., Hövelmann, U., Willard, J., Plum‐Mörschel, L., Knudsen, K. M., Bandak, B., & Tehranchi, R. (2021) · Diabetes Care · doi:10.2337/dc20-2995 · Cited by 54
Self-citationUpdate on the management of diabetes in long-term care facilities
Idrees, T., Castro-Revoredo, I. A., Migdal, A. L., Moreno, E. M., & Umpierrez, G. E. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002705 · Cited by 44
Advances in Type 1 Diabetes Technology Over the Last Decade
Zimmerman, C., University of Florida, G., Albanese-O’Neill, A., University of Florida, G., Haller, M. J., & University of Florida, G. (2019) · European Endocrinology · doi:10.17925/ee.2019.15.2.70 · Cited by 47
“Phase II trials have been completed and demonstrated similar pharmacokinetics to current glucagon formulations with similar side effects of dosedependent nausea and vomiting.(50) Xeris (Chicago, Illinois, USA) has developed a stable liquid glucagon that is a native human glucagon dissolved in a carrier solution, dimet…”
BackgroundNovel preparations of glucagon for the prevention and treatment of hypoglycemia
Hawkes, C. P., De Leon, D. D., & Rickels, M. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1216-4 · Cited by 46
Thieu, V. T., Mitchell, B. D., Varnado, O. J., & Frier, B. M. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13941 · Cited by 44
“In a single-centre, randomized, double-blind study, the PK/PDproperties of 0.1, 0.3, 0.6 and 1.0 mg dasiglucagon, as well as its safety and tolerability, were compared with those of 0.5 and 1.0 mg GlucaGen in the treatment of insulin-induced hypoglycaemia in patients with T1D.84 Dasiglucagon produced a dose-dependent…”
BackgroundInfluentialEgelund, P. H. G., Jadhav, S. V., Martin, V., Johansson, H., Richner, F., Quement, S. T. L., Dettner, F., Lechner, C. C., Schoenleber, R. O., & Pedersen, D. S. (2021) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.1c04770 · Cited by 45
Glucose-Driven Droplet Formation in Complexes of a Supramolecular Peptide and Therapeutic Protein
Yu, S., Chen, W., Liu, G., Flores, B., DeWolf, E. L., Fan, B., Xiang, Y., & Webber, M. J. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c13139 · Cited by 46
Glucagon-based therapy: Past, present and future
Patil, M., Deshmukh, N., Patel, M. V., & Sangle, G. V. (2020) · Peptides · doi:10.1016/j.peptides.2020.170296 · Cited by 37
Farias, A. P. D. C., & THORNTON, P. S. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00334-w · Cited by 38
New uses and formulations of glucagon for hypoglycaemia
Beato-Víbora, P. I., & Arroyo-Díez, F. J. (2019) · Drugs in Context · doi:10.7573/dic.212599 · Cited by 40
Battelino, T., Tehranchi, R., Bailey, T. S., Dovč, K., Melgaard, A. E., Stone, J. Y., Woerner, S., Berge, T. V. D., DiMeglio, L. A., & Danne, T. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13220 · Cited by 37
“Phase 2 results in adults were used to determine sample size.(10) These results showed that the median time to an increase in PG of 20 mg/dL was approximately 10 min for dasiglucagon 0.”
BackgroundMethodInfluentialUse of Glucagon in Patients With Type 1 Diabetes
Haymond, M. W., Liu, J., Bispham, J. A., Hickey, A., & McAuliffe‐Fogarty, A. H. (2018) · Clinical Diabetes · doi:10.2337/cd18-0028 · Cited by 33
“” Once glucagon is injected, the blood glucose begins to rise within 10–15 minutes, peaking at 45–60 minutes with a total duration of effect of ~1–2 hours (4,5).”
BackgroundThe automated pancreas: A review of technologies and clinical practice
Biester, T., Tauschmann, M., Chobot, A. P., Kordonouri, O., Danne, T., Kapellen, T. M., & Dovč, K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14576 · Cited by 34
“5 hours allows flexibility for use in a bihormonal pump (Table 2).(70)”
Complexities in the medical management of hypoglycaemia due to congenital hyperinsulinism
Worth, C., Yau, D., Salomon‐Estebanez, M., O’Shea, E., Cosgrove, K. E., Dunne, M. J., & Banerjee, I. (2020) · Clinical Endocrinology · doi:10.1111/cen.14152 · Cited by 31
Glucagon: Its evolving role in the management of hypoglycemia
Isaacs, D. M., Clements, J. N., Turco, N., & Hartman, R. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2534 · Cited by 31
Insulin-and-Glucagon Artificial Pancreas Versus Insulin-Alone Artificial Pancreas: A Short Review
Haidar, A. (2019) · Diabetes Spectrum · doi:10.2337/ds18-0097 · Cited by 30
Hövelmann, U., Olsen, M. B., Mouritzen, U., Lamers, D., Kronshage, B., & Heise, T. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13562 · Cited by 28
“6 mg, which showed similar effects to those of 1-mg doses of existing glucagon formulations in the previous trial.(19) For comparison, freshly reconstituted commercially available glucagon (Eli Lilly, Indianapolis, Indiana; hereafter referred to as “commercial glucagon”) was used at the same small doses (0.”
BackgroundMethodResultSelf-citationSala, L. L., & Pontiroli, A. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910643 · Cited by 29
“Dasiglucagon was approved in the US in 2021 [77].”
BackgroundSamson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
Steineck, I. I. K., Ranjan, A. G., Schmidt, S., Clausen, T. R., Holst, J. J., & Nørgaard, K. (2019) · Diabetologia · doi:10.1007/s00125-018-4807-8 · Cited by 27
Blair, H. A. (2021) · Drugs · doi:10.1007/s40265-021-01531-z · Cited by 24
Glucose‐Triggered Gelation of Supramolecular Peptide Nanocoils with Glucose‐Binding Motifs
Yu, S., Ye, Z., Roy, R., Sonani, R. R., Pramudya, I., Xian, S., Xiang, Y., Liu, G., Flores, B., Nativ‐Roth, E., et al. (2023) · Advanced Materials · doi:10.1002/adma.202311498 · Cited by 23
Christiansen, M. P., Cummins, M., Prestrelski, S., Close, N. C., Nguyen, A., & Junaidi, K. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002137 · Cited by 22
Diabetes: how to manage patients experiencing hypoglycaemia
Lowe, R. N., Williams, B., & Claus, L. W. (2022) · Drugs in Context · doi:10.7573/dic.2021-9-11 · Cited by 27
Dasiglucagon: an effective medicine for severe hypoglycemia
Xu, B., Tang, G., & Chen, Z. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03183-0 · Cited by 20
Translational aspects of glucagon: current use and future prospects
Kaur, J., & Seaquist, E. R. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0278 · Cited by 21
Pancreas transplantation today: quo vadis?
Al-Naseem, A., Attia, A., Gonnah, A. R., Al-Naseem, A. O. A. S., Spiers, H. V. M., Gruessner, A. C., Leelarathna, L., Thabit, H., & Augustine, T. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad032 · Cited by 21
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Long-Term Safety and Tolerability of Dasiglucagon, a Stable-in-Solution Glucagon Analogue
Castle, J. R., & Elander, M. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0363 · Cited by 18
Nielsen, C. K., Øhrstrøm, C. C., Kielgast, U. L., Hansen, D. L., Hartmann, B., Holst, J. J., Lund, A., Vilsbøll, T., & Knop, F. K. (2022) · Diabetes Care · doi:10.2337/dc21-2252 · Cited by 19
Nielsen, C. K., Øhrstrøm, C. C., Houji, I. J. K., Helsted, M. M., Krogh, L. S. L., Johansen, N. J., Hartmann, B., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2023) · Diabetes Care · doi:10.2337/dc23-1193 · Cited by 19
Structural Refinement of Glucagon for Therapeutic Use
Chabenne, J. R., Mroz, P. A., Mayer, J. P., & DiMarchi, R. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01493 · Cited by 19
Bailey, T. S., Willard, J., Klaff, L. J., Stone, J. Y., Melgaard, A. E., & Tehranchi, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14475 · Cited by 16
Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies
Demirbilek, H., Vurallı, D., Haris, B., & Hussain, K. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s313837 · Cited by 23
“5–1 mg) in insulin-induced hypoglycaemia.(76) Dasiglucagon showed a dosedependent and quick increase in plasma glucose concentrations in this study.”
BackgroundMoscardó, V., Díez, J.-L., & Bondía, J. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819879093 · Cited by 17
“Note that now equation (2) can be expressed as a singleinput-single-output system in terms of the new virtual control action:”
BackgroundHerrero, P., El-Sharkawy, M., Daniels, J., Jugnee, N., Uduku, C. N., Reddy, M., Oliver, N. S., & Georgiou, P. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819881456 · Cited by 17
“Although a dualhormone AP has a potential benefit over its insulin-only counterpart, its development and commercialization has been delayed by the lack of a commercial stable glucagon solution.(22) Another challenge AP systems face is the significant interday variability in insulin requirements that people with diabet…”
BackgroundTHORNTON, P. S., León, D. D. D., Empting, S., Zangen, D., Kendall, D. M., Birch, S., Bøge, E., Ivkovic, J., & Banerjee, I. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad648 · Cited by 13
Glucagon for hypoglycaemia treatment in type 1 diabetes
Ranjan, A. G., Schmidt, S., & Nørgaard, K. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3409 · Cited by 17
“Pharmacokinetic and pharmacodynamic studies have demonstrated that Dasiglucagon increases plasma glucose in a dose‐ dependent manner in persons with T1D.(68) Compared with GlucaGen, Dasiglucagon has a slightly higher potency and a longer‐lasting glucose elevating effect but restores normo‐glycaemia at a similar speed.”
BackgroundAID(„automated insulin delivery“)-Systeme in der Diabetologie
Biester, T., Dovč, K., Chobot, A. P., Tauschmann, M., & Kapellen, T. M. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00777-1 · Cited by 12
New Developments in Glucagon Treatment for Hypoglycemia
Hayward, L., & Wilson, L. M. (2022) · Drugs · doi:10.1007/s40265-022-01754-8 · Cited by 11
Laugesen, C., Ranjan, A. G., Schmidt, S., & Nørgaard, K. (2022) · Diabetes Care · doi:10.2337/dc21-2304 · Cited by 13
Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes
Li, S., Hu, Y., Tan, X., Wang, D., Hu, J., Zou, P., & Wang, L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1747432 · Cited by 11
Chemical Synthesis and Characterization of a Nonfibrillating Glycoglucagon
Liu, M., Zhao, P., Uddin, M. H., Li, W., Lin, F. W., Chandrashekar, C., Nishiuchi, Y., Kajihara, Y., Forbes, B. E., Wootten, D. L., et al. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00419 · Cited by 10
Giménez, M., Khunti, K., Matsuhisa, M., Chenji, S., Syring, K. E., & Yan, Y. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01466-6 · Cited by 11
Glucagon delivery – An overview of current and future devices
Рабинович, А. Л., & Priefer, R. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.05.028 · Cited by 8
Teigen, I. A., Åm, M. K., Carlsen, S. M., & Christiansen, S. C. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00692-2 · Cited by 8
Heller, S. R., Battelino, T., Bailey, T. S., Pieber, T. R., Hövelmann, U., Plum‐Mörschel, L., Melgaard, A. E., Aronson, R., DiMeglio, L. A., Johansen, T., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14987 · Cited by 7
“The inclusion of the non-placebocontrolled trials was supported by the consistency of the primary efficacy outcomes across all four trials (Table S2) as well as by their similar trial designs (Figure 1B) and participant characteristics (Table S2).(20,23,25,26) Participants in the placebo-controlled trials were unevenl…”
BackgroundMethodResultSelf-citationThe prescription rates of glucagon for hypoglycemia by pediatricians and physicians are low in Japan
Matsumoto, M., Awano, H., Hirota, Y., Nagai, M., Bo, R., Matsuoka, A., Hamaguchi, T., Takeuchi, T., Nakagawa, Y., Ogawa, W., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1793-z · Cited by 7
Furió-Novejarque, C., Sanz, R., Ritschel, T. K. S., Reenberg, A. T., Ranjan, A. G., Nørgaard, K., Díez, J.-L., Jørgensen, J. B., & Bondía, J. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106605 · Cited by 7
Huh, K. Y., Hwang, J. G., Shin, W., Baek, S. J., Choi, J., Lee, N., Cho, Y. M., & Lee, H. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14590 · Cited by 8
“Dasiglucagon rapidly increased plasma glucose, with its peak effect reached at 10 minutes postdose.(36) Gvoke HypoPen (autoinjector)(12) and Baqsimi (nasal powder)(37) have been used for a similar purpose.”
BackgroundMolecular engineering of designer diabetes therapeutics
DeWolf, E. L., Webber, B., & Webber, M. J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114705 · Cited by 5
Recent Trends in Peptide Drug Discovery and Development
Madge, H. Y. R., & Muttenthaler, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674541-00023 · Cited by 6
León, D. D. D., Banerjee, I., Kummer, S., Birch, S., Bøge, E., Ivkovic, J., Kendall, D. M., & THORNTON, P. S. (2024) · Yearbook of pediatric endocrinology · doi:10.1530/ey.23.2.9 · Cited by 5
Structural insights into ligand efficacy and activation of the glucagon receptorPreprint
Hilger, D., Kumar, K. K., Hu, H., Pedersen, M. F., Giehm, L., Mathiesen, J. M., Skiniotis, G., & Kobilka, B. K. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/660837 · Cited by 5
Negative allosteric modulation of the glucagon receptor by RAMP2Preprint
Kumar, K. K., O’Brien, E. S., Habrian, C. H., Latorraca, N. R., Wang, H., Tuneew, I., Montabana, E. A., Marqusee, S., Hilger, D., Isacoff, E. Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.30.505955 · Cited by 5
“001% CHS, 20 μM diC8PtdIns(4,5)P2, 100 μM TCEP and 1 mM ATP) and agonist ZP3780 was added to 10 μM final.”
MethodKadu, P., Webber, B., Chen, W., Kovrigin, E. L., & Webber, M. J. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c07167 · Cited by 4
Hormones, Blood Products, and Therapeutic Enzymes
Silva, A. C., Costa, C. P., Almeida, H., Moreira, J. N., & Lobo, J. M. S. (2019) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2019_111 · Cited by 5
Jacobasch, G., Bleiber, R., & Schönian, G. (1982) · PubMed · Cited by 5
Teigen, I. A., Riaz, M., Åm, M. K., Christiansen, S. C., & Carlsen, S. M. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.986858 · Cited by 5
“Unlike insulin, glucagon is absorbed rapidly after SC administration, reaching maximum plasma concentrations in humans at approximately 10–20 min (Simmons and Williams, 1992; Graf et al., 1999; El-Khatib et al., 2010; El Youssef et al., 2014; Blauw et al., 2016; Castle et al., 2016; Ranjan et al., 2016; Hövelmann et a…”
BackgroundDasiglucagon in severe hypoglycemia: a profile of its use
Syed, Y. Y. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00894-x · Cited by 4
Dholariya, S. J., Parchwani, D. N., Dutta, S., & Singh, R. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2138343 · Cited by 3
“Furthermore, dasiglucagon generated a dose-dependent, persistent, and overall higher glycemic response compared to conventional glucagon in the pharmacodynamic trial, further minimizing the risk of recurrent hypoglycemia [33].”
BackgroundDiscovery of insulin 100 years on
Russell-Jones, D. L., & Bawlchhim, Z. (2022) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2022-141651 · Cited by 3
A Computational Glucoregulatory Model of Liver and Glucagon for the Evaluation of Therapeutics
Gong, X., Alizadehmojarad, A. A., Machado, M., Yang, S., & Strano, M. S. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00177 · Cited by 2
Advances in Pharmacotherapy for Congenital Hyperinsulinism
González-Llorens, N., Yau, D., Clemente, M., Demirbilek, H., Banerjee, I., & Shah, P. (2025) · Pediatric Drugs · doi:10.1007/s40272-025-00727-0 · Cited by 2
“This modification allows dasiglucagon to be formulated as a ready-to-use liquid for subcutaneous (SC) injection or continuous SC infusion [50, 51].”
DeWolf, E. L., Chen, W., Webber, B., Power, E. M., Kilmer, R., Kadu, P., Xian, S., & Webber, M. J. (2026) · Small Science · doi:10.1002/smsc.202500555 · Cited by 2
Tehranchi, R., Pettersson, J., Melgaard, A. E., Seitz, F., Valeur, A., & Maarbjerg, S. (2022) · Current Therapeutic Research · doi:10.1016/j.curtheres.2022.100668 · Cited by 2
Dasiglucagon: A Novel Ready-to-Use Treatment for Severe Hypoglycemia
Goodhart, A. L. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221108425 · Cited by 2
Clinical Trials: Essential Stage in Development of Drug
Tamboli, S. S., Surwade, A. B., Mahale, K. J., Khairnar, K. B., Avhad, K., Avhad, A. V., Chavan, A. G., Kaluse, P. S., Darekar, A. B., Ugale, P. G., et al. (2022) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v12i4-s.5621 · Cited by 1
Diabetes Technology and Therapy in the Pediatric Age Group
Maahs, D. M., Prahalad, P., Schweiger, D. Š., & Shalitin, S. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.2508 · Cited by 1
Schaumleffel, C. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s325865 · Cited by 1
“However, for this study, dasiglucagon was found to have a longer lasting effect on plasma blood glucose levels, indicating the longer lasting effect of dasiglucagon may reduce the risk of recurrent hypoglycemia after administration.(6) One dose of 0.”
BackgroundVaras, N., Jarosinski, M. A., Chen, Y., Ni, C., Grabowski, R., Tai, N., Herzog, R. I., Ismail‐Beigi, F., Yang, Y., Cherrington, A. D., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00362 · Cited by 3
Peptide-Tools–Web Server for Calculating Physicochemical Properties of Peptides
Frolov, A. I., Morley, J., dos Santos, A. G., Genapathy, S., & Ghiandoni, G. M. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02296 · Cited by 3
The expanding landscape of the glucagon signaling network: mechanisms and outcomes
Foollee, A., Wu, Y., Rusu, P. M., & Rose, A. J. (2026) · Endocrinology · doi:10.1210/endocr/bqag041 · Cited by 1
Baker, D. E. (2021) · Hospital Pharmacy · doi:10.1177/00185787211046857 · Cited by 1
Pharmacodynamic Evaluation: Diabetic Methodologies
SANDOW, J. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_33 · Cited by 1
Algorithmen für die automatisierte Insulindosierung (AID): ein Überblick
Thomas, A., & Heinemann, L. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00966-6 · Cited by 2
Maji, S., Mohanty, R. R., & Maiti, R. (2023) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2023.2023-7-84 · Cited by 1
“After the final screening, five studies 15,17-19 Studies that used different doses and more than one comparator group were considered separate units; accordingly, a total of 11 units of analysis were studied in this meta-analysis (Figure 1).”
MethodKalisvaart, D., Bonekamp, J. G., & Grammatico, S. (2023) · IEEE Conference on Control Technology and Applications (CCTA) · doi:10.1109/ccta54093.2023.10252997 · Cited by 2
“Indeed, it was shown in [20] that glucagon helps to recover from hypoglycemia faster.”
BackgroundClinical Pharmacology of Glucagon
Kronfol, M. M., Chow, E. C. Y., Lau, S. W. J., Nounou, M. I., Vaidyanathan, J., & Seo, S. K. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3340 · Cited by 1
León, D. D. D., Banerjee, I., Kummer, S., Birch, S., Bøge, E., Ivkovic, J., Kendall, D. M., & THORNTON, P. S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf102 · Cited by 1
Faggionato, E., Tonello, A., Laurenti, M. C., Vella, A., & Dalla Man, C. (2025) · American Journal of Physiology - Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00172.2025
Strategies to mitigate hypoglycaemia in the artificial pancreas
Bondía, J., & Vehí, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00018-1
Pharmacodynamic Evaluation: Diabetic Methodologies
SANDOW, J. (2019) · Springer eBooks · doi:10.1007/978-3-319-56637-5_33-1
Metadata
- Authors
- Hövelmann, U., Bysted, B. V., Mouritzen, U., Macchi, F., Lamers, D., Kronshage, B., Møller, D. V., & Heise, T.
- Affiliations
- Profil Institute for Metabolic Research (DE)
- Zealand Pharma (Denmark) (DK)
- Corresponding author
- Hövelmann, Ulrike
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-22
- Volume
- 41
- Issue
- 3
- Pages
- 531-537
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2781395153
- Cited by
- 115
- References
- 26
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 7 · 2023: 17 · 2022: 18 · 2021: 26 · 2020: 7 · 2019: 15 · 2018: 6
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- dasiglucagon, glucagon analog, severe hypoglycemia, type 1 diabetes, insulin-induced hypoglycemia, pharmacokinetics, pharmacodynamics, subcutaneous injection, salvage therapy, glycemic response, nausea, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glucagon, Half-Life, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.